PMID- 37694148 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230913 IS - 2589-0042 (Electronic) IS - 2589-0042 (Linking) VI - 26 IP - 9 DP - 2023 Sep 15 TI - Immune-active tumor-adjacent tissues are associated with favorable prognosis in stage I lung squamous cell carcinoma. PG - 107732 LID - 10.1016/j.isci.2023.107732 [doi] LID - 107732 AB - The immunogenomic features of tumor-adjacent lungs (TALs) in stage I lung squamous cell carcinoma (LUSC) are not clear. Multiomics analyses of tumor tissues and paired TALs from 59 stage I LUSC patients were performed. Compared to tumors, TALs exhibited a better-preserved immune contexture indicated by upregulation of immune pathways, increased immune infiltration, and higher expression of immune effector molecules. Notably, TALs had no mutations in PTEN and KEAP1, a lower incidence of human leukocyte antigen (HLA) loss and higher expression of HLA class I genes, major histocompatibility complex (MHC) I chaperones, and interferon (IFN)-gamma-associated genes. Digital spatial profiling validated the generally higher immune infiltration in TALs and revealed a higher level of immune heterogeneity in LUSC tumors. Importantly, patients with higher immune infiltration in TALs had significantly longer survival, while high immune heterogeneity was associated with inferior patient survival. Our work can be considered in the selection of patients for adjuvant therapy, especially immunotherapy. CI - (c) 2023 The Authors. FAU - Ying, Lisha AU - Ying L AD - Zhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. FAU - Zhang, Chunliu AU - Zhang C AD - Geneplus-Beijing Institute, Beijing, China. FAU - Reuben, Alexandre AU - Reuben A AD - Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. FAU - Tian, Yiping AU - Tian Y AD - Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. FAU - Jin, Jiaoyue AU - Jin J AD - Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. FAU - Wang, Canming AU - Wang C AD - Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. FAU - Bai, Jing AU - Bai J AD - Geneplus-Beijing Institute, Beijing, China. FAU - Liu, Xinyuan AU - Liu X AD - Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. AD - The Second Clinical Medical College, Zhejiang Chinese Medicine University, Hangzhou, Zhejiang 310053, China. FAU - Fang, Jianfei AU - Fang J AD - Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. FAU - Feng, Tingting AU - Feng T AD - Zhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. AD - Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. FAU - Xu, Chenyang AU - Xu C AD - Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. FAU - Zhu, Rui AU - Zhu R AD - Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. FAU - Huang, Minran AU - Huang M AD - Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. FAU - Lyu, Yingqi AU - Lyu Y AD - Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. AD - Department of Oncology, The First Clinical Medical College of Wenzhou Medical University, Wenzhou, Zhejiang 325015, China. FAU - Lu, Tingting AU - Lu T AD - Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. AD - Department of Oncology, The First Clinical Medical College of Wenzhou Medical University, Wenzhou, Zhejiang 325015, China. FAU - Pan, Xiaodan AU - Pan X AD - Human Tissue Bank, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. FAU - Zhang, Jianjun AU - Zhang J AD - Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. AD - Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. FAU - Su, Dan AU - Su D AD - Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China. LA - eng PT - Journal Article DEP - 20230825 PL - United States TA - iScience JT - iScience JID - 101724038 PMC - PMC10483046 OTO - NOTNLM OT - Immunology OT - Oncology OT - Transcriptomics COIS- Dr. Reuben serves on the scientific advisory board and has received honoraria from Adaptive Biotechnologies. Dr. Zhang reports grants from Merck, Novartis, Johnson and Johnson, personal fees from BMS, AZ, Novartis, Johnson and Johnson, GenePlus, Innovent, outside the submitted work. EDAT- 2023/09/11 06:42 MHDA- 2023/09/11 06:43 PMCR- 2023/08/25 CRDT- 2023/09/11 05:03 PHST- 2023/03/05 00:00 [received] PHST- 2023/07/07 00:00 [revised] PHST- 2023/08/21 00:00 [accepted] PHST- 2023/09/11 06:43 [medline] PHST- 2023/09/11 06:42 [pubmed] PHST- 2023/09/11 05:03 [entrez] PHST- 2023/08/25 00:00 [pmc-release] AID - S2589-0042(23)01809-6 [pii] AID - 107732 [pii] AID - 10.1016/j.isci.2023.107732 [doi] PST - epublish SO - iScience. 2023 Aug 25;26(9):107732. doi: 10.1016/j.isci.2023.107732. eCollection 2023 Sep 15.